Scientific Vita
Con­tact
Info

Dr.

Sven Nahnsen

Project: INF

Academic Education and Scientific Degrees
2010
Ph.D. in Bioinformatics, University of Tübingen, Germany
2007-2010
PhD student, Proteome Center Tübingen/Center for Bioinformatics, University of Tübingen
2006
Diplôme d’Ingénieur – Biotechnology, University of Strasbourg, France
2003-2006
Trinational (France, Germany, Switzerland) studies of Biotechnology, École supérieure de biotechologie de Strasbourg, France
2006
Diploma thesis, University of Cambridge, UK
2003
Vordiplom in Biomathematics, University of Greifswald, Germany
2001-2003
Studies of Biomathematics, University of Greifswald, Germany

Professional Career
2012-present
Head, Quantitative Biology Center (QBiC), Tübingen, Germany
2013-2015
Founder and CEO, CodeMS UG (haftungsbeschränkt), Berlin, Germany
2011-2012
Senior Research Scientist, Center for Bioinformatics, University of Tübingen, Germany
2007-2010
Research Scientist, Proteome Center Tübingen and Software Developer, Center for Bioinformatics, University of Tübingen, Germany
2006
Research assistant, University of Cambridge, UK
Address
Tübingen University
Auf der Morgenstelle 10
72076 Tübingen
Phone
+49/7071/297 2163
eMail
Sven.Nahnsen@uni-tuebingen.de
Awards and Appointments
2016
Founder, German Network for Bioinformatics Core Units
2016
Grant reviewer, DFG
2014
Member, Center for Bioinformatics, Tübingen
2004-2006
EUCOR Fellowship, Upper Rhine Universities
2006
Student research fellowship, University of Cambridge, UK

Others
2012-present
Head, Quantitative Biology Center (QBiC), Tübingen, Germany
2013-2015
Founder and CEO, CodeMS UG (haftungsbeschränkt), Berlin, Germany
2011-2012
Senior Research Scientist, Center for Bioinformatics, University of Tübingen, Germany
2007-2010
Research Scientist, Proteome Center Tübingen and Software Developer, Center for Bioinformatics, University of Tübingen, Germany
2006
Research assistant, University of Cambridge, UK

Patents
Schindler M, Codrea MC, Nahnsen S, Koppensteiner H, (AKZ: 10 2016 105.069.5), Antivirale Immuntherapie durch Membranrezeptoroligation. Pending.